19/03/2020
ished on Mar 17, 2020
U.S. researchers administered the first shot to
the first person in a test of an experimental
coronavirus vaccine. With a careful jab on a
healthy volunteer's arm, scientists at the Kaiser
Permanente Washington Research Institute
began an anxiously-awaited first-stage study of
a potential COVID-19 vaccine. Even if the
research goes well, a vaccine wouldn't be
available for widely use for 12-18 months,
according to the U.S. National Institutes of
Health. The trial vaccine, code-named
mRNA-1273, was developed by the NIH and
Massachusetts-based biotechnology company
Moderna Inc. There's no chance participants
can get infected from the shots because they
don't contain the coronavirus itself. Kaiser
Permanente screened dozens of people, looking
for those who have no chronic health problems
and aren't currently sick. Participants are paid
100 U.S. dollars for each clinic visit during the
study.
